Warren P Mason1. 1. Princess Margaret Hospital, Department of Medicine, 610 University Avenue, Suite 18-717, Toronto, Ontario, M5G 2M9, Canada. warren.mason@uhn.on.ca
Abstract
BACKGROUND: Malignant gliomas are amongst the most devastating and intractable of all cancers. The most common malignant glioma, glioblastoma multiforme (GBM), is associated with a median survival in the range of 12-15 months. Survival for patients with GBM has improved with the addition of temozolomide chemotherapy to post-operative radiotherapy. Further advances in the treatment of malignant glioma will hinge on the discovery of novel and likely targeted therapies with activity against these diseases. OBJECTIVE: Review recent published experience using targeted therapeutics for malignant glioma. METHODS: Key studies from a Medline review of targeted therapies for malignant glioma performed between 2000 and the present are summarised in this review. CONCLUSIONS: Experience with targeted therapeutics for malignant glioma has been to date disappointing. These agents are generally well tolerated, but activity is limited. Novel therapeutics with activity against malignant gliomas must be identified to improve prognosis for patients with these diseases.
BACKGROUND:Malignant gliomas are amongst the most devastating and intractable of all cancers. The most common malignant glioma, glioblastoma multiforme (GBM), is associated with a median survival in the range of 12-15 months. Survival for patients with GBM has improved with the addition of temozolomide chemotherapy to post-operative radiotherapy. Further advances in the treatment of malignant glioma will hinge on the discovery of novel and likely targeted therapies with activity against these diseases. OBJECTIVE: Review recent published experience using targeted therapeutics for malignant glioma. METHODS: Key studies from a Medline review of targeted therapies for malignant glioma performed between 2000 and the present are summarised in this review. CONCLUSIONS: Experience with targeted therapeutics for malignant glioma has been to date disappointing. These agents are generally well tolerated, but activity is limited. Novel therapeutics with activity against malignant gliomas must be identified to improve prognosis for patients with these diseases.
Authors: Matej Vrabec; Sofie Van Cauter; Uwe Himmelreich; Stefaan W Van Gool; Stefan Sunaert; Steven De Vleeschouwer; Dušan Suput; Philippe Demaerel Journal: Neuroradiology Date: 2010-11-25 Impact factor: 2.804
Authors: Desirée Magalhães Dos Santos; Camila Valesca Jardim Rocha; Elita Ferreira da Silveira; Marcelo Augusto Germani Marinho; Marisa Raquel Rodrigues; Nichole Osti Silva; Ailton da Silva Ferreira; Neusa Fernandes de Moura; Gabriel Jorge Sagrera Darelli; Elizandra Braganhol; Ana Paula Horn; Vânia Rodrigues de Lima Journal: J Membr Biol Date: 2018-02-08 Impact factor: 1.843
Authors: Stella Sun; T S Wong; X Q Zhang; Jenny K S Pu; Nikki P Lee; Philip J R Day; Gloria K B Ng; W M Lui; Gilberto K K Leung Journal: J Neurooncol Date: 2011-10-07 Impact factor: 4.130
Authors: Luciana F Romão; Fabio A Mendes; Natalia M Feitosa; Jane Cristina O Faria; Juliana M Coelho-Aguiar; Jorge Marcondes de Souza; Vivaldo Moura Neto; José Garcia Abreu Journal: PLoS One Date: 2013-01-31 Impact factor: 3.240